Matthew R Levengood

7PUBLICATIONS
52CO-AUTHORS
GlycoconjugatesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 23, 2026
Discovery of a Novel Tripeptide Linker that Broadens the Therapeutic Window of Auristatin-Based Antibody-Drug Conjugates by Reducing Bone Marrow Toxicity.

|Apr 20, 2026
An Integrin β6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer.

|Apr 28, 2025
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.

Sherif Abdelhamed, Xinqun Zhang, Weiping Zeng

|Oct 28, 2024
Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47.

Matthew R Levengood, Christopher M Carosino, Xinqun Zhang

|May 24, 2024
Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation.

Philip N Moquist, Xinqun Zhang, Chris I Leiske

|May 29, 2019
A coiled-coil masking domain for selective activation of therapeutic antibodies.

Vivian H Trang, Xinqun Zhang, Roma C Yumul

Pageof 2

Frequent Collaborators

3 joint publications

Christopher M Carosino

3 joint publications

David J Ortiz

2 joint publications

Xinqun Zhang

2 joint publications

Devra J Olson